Real-World Economic Burden and Healthcare Resource Utilization of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the United States
This analysis reveals that RC costs were primarily driven by inpatient services, particularly inpatient facility costs. For trimodal therapy, outpatient costs predominated, driven by drugs administered and outpatient radiology facilities. The considerable costs and utilization associated with these treatments underscore the need for value-based therapeutic approaches aimed at enhancing patient outcomes.
Authors
- Hayden W. Hyatt (ORCID: https://orcid.org/0000-0001-8075-5670)
- Kunal J. Lodaya (ORCID: https://orcid.org/0000-0001-5049-5206)
- Farah Pathan (ORCID: https://orcid.org/0000-0003-0498-7722)
- Ian Weimer (ORCID: https://orcid.org/0000-0002-2725-7207)
- Stephen B. Williams (ORCID: https://orcid.org/0000-0002-2683-2185)
- Haojie Li (ORCID: https://orcid.org/0000-0001-6233-8603)
- Puneet K. Singhal
- Halit O. Yapici (ORCID: https://orcid.org/0009-0003-2447-7962)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Mass General Brigham (US)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- Urology
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.urology.2025.03.028
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02